Synonyms: Fareston
CAS: 89778-27-8
MF: C26H28ClNO.C6H8O7
MW: 598.09
Assay: 99%
Grade: Pharmaceutical Grade
Appearance: White Powder
Usage: Pharmaceutical Raw Materials
Melting Point: 158-164 dec.
Boiling Point: 535.1 dec. at 760 mmHg
Density: 1.045g/cm3
Refractive Index: 1,416-1,418
Toremifene Citrate Effect
Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.
It has already been covered that Toremifene is a SERM, and serves to block Estrogen at various receptor sites in certain tissues within the body (breast tissue in particular). As a layman explanation, Toremifene pretends to be a 'fake' Estrogen that occupies Estrogen receptors within breast tissue. With these receptors occupied by Toremifene, real Estrogen cannot perform their jobs there. Toremifene does not reduce total blood plasma levels of Estrogen. In addition to being antagonistic to Estrogen receptors in breast tissue, it is also antagonistic to Estrogen at the hypothalamus gland (this essentially 'tricks' the hypothalamus into thinking there is little or no circulating Estrogen levels in the body, causing it to increase its manufacture of Testosterone so that it can utilize aromatization to restore these levels.
Toremifene Citrate exerts its effects by antagonizing the estrogen receptor in some tissues, and agonizing it in others. In this way, certain estrogenic pathways are activated and others are blockaded. It seems to exert estrogenic effects on blood lipids, reducing LDL and total cholesterol, as well as estrogenic effects on bone, improving density. It would also appear to exert anti-estrogenic effects in breast tissue, displacing the traditional effects of estrogen, effectively helping prevent breast cancer in postmenopausal women.
Fareston Administration
In the fight against breast cancer, standard Fareston doses will normally be 60mg per day. The total duration of use is unpredictable and will be based on patient need. It's not uncommon for treatment to last a year or two and then AI's to be added if needed. Once the cancer is in remission, compounds like Fareston are commonly used to support the improved state.
For the anabolic steroid user combating gynecomastia, standard Fareston doses will fall in the 30-60mg per day range and will work very well for most men. If this is not enough protection, while you could try increasing the dose your best bet would be to move to AI use. You will find Fareston works very well in combating gynecomastia due to the use of any testosterone, Dianabol and Anadrol. You will also find it works well with Equipoise and Deca Durabolin. However, as Deca Durabolin is also a progestin, men who are very sensitive to that hormone may need an AI. The same can be said of the Trenbolone hormone. Trenbolone does not aromatize, but it is a progestin. Further, the use of an aromatizing steroid with a compound like Trenbolone can increase the risk of gynecomastia in some men. While many will not need gynecomastia protection due to progestins and will get by with SERM's to combat aromatase, some sensitive men will need an AI. Regardless, if Fareston works for you it will cover the entire breadth of the cycle from start to finish.
No comments:
Post a Comment